114 results
Page 3 of 6
8-K
EX-99.1
c40638fm
13 Oct 22
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
8:32am
424B5
e3ldjj lt
12 Aug 22
Prospectus supplement for primary offering
8:31am
8-K
ezw3etc
25 May 22
Regulation FD Disclosure
7:02am
8-K
EX-99.1
nsltw3ay ye655
25 May 22
Regulation FD Disclosure
7:02am
8-K
EX-1.1
azrdo
13 Apr 22
Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering
4:26pm
424B5
ghwb 92slej0
13 Apr 22
Prospectus supplement for primary offering
4:22pm
8-K
EX-99.1
3cinfm 3zyts7rz
30 Mar 22
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
4:05pm
8-K
EX-99.2
g2hmk47ae3
30 Mar 22
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
4:05pm
8-K
jz0747o
28 Feb 22
Entry into a Material Definitive Agreement
8:30am
424B5
z09m5yo041 qe
21 Oct 21
Prospectus supplement for primary offering
4:26pm
8-K
EX-1.1
oj3p rg4m4n
21 Oct 21
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
4:24pm
424B5
pw948xb 25m54ylertoa
20 Oct 21
Prospectus supplement for primary offering
4:15pm
8-K
EX-99.1
qll6bsaem8vz y08
15 Sep 21
Regulation FD Disclosure
4:05pm
S-3ASR
bxx5o
10 Aug 21
Automatic shelf registration
5:25pm